GSK plc · GSK · Next earnings

GSK plc reports Wednesday, Oct 28, 2026

GSK reports before market open with consensus EPS at $1.33 and revenue at $11.78B. Last quarter: GSK reaffirms 2026 guidance as specialty medicines drive Q3 growth

Reports Before market open0 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $1.33 Calendar consensus
Consensus revenue $11.78B Calendar consensus
Report date Oct 28, 2026 Wednesday, date estimated
Session Before market open 0 days away

Where GSK left off: FY2026 Q3

Full report

GSK reaffirms 2026 guidance as specialty medicines drive Q3 growth

EPS surprise — Reported — vs $1.33
Revenue surprise — Reported — vs $11.78B
Stock move -4.3% Event window
Subsequent drift 0.0% Up to 20 sessions

2026 full-year guidance was reaffirmed, with sales expected in the upper half of the range.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Pricing pressure and IRA rebates may weigh on TRELEGY and other general medicines.
  • Hibsago carries monitoring and safety considerations, while China approval remains pending.
  • Higher R&D spending, acquisition-related interest expense, and possible launch delays could pressure execution.

Questions analysts left open

  • Timing and data readouts for four-monthly HIV PrEP and treatment studies.
  • The effect of Exdensur’s J-code on sales acceleration.
  • Shingrix inventory, IRA rebates, and the financial impact of the Nuvalent acquisition.

Ask FN2 about GSK next report

Transcript, numbers and history already loaded
What should I watch for in GSK's next earnings report?How did GSK guide last quarter, and is consensus above or below that?Give me the bull and bear case going into GSK earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the GSK recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent GSK quarters

All GSK earnings
-4.3%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.